Home
NSE: ABBOTINDIA
ISIN
NSE: ABBOTINDIA
Share Price
1M
1Y
3Y
5Y
Date | Price (₹) |
---|---|
27 Jan 2025 | 26532.6 |
24 Jan 2025 | 27272.7 |
23 Jan 2025 | 27838.35 |
22 Jan 2025 | 27745.95 |
21 Jan 2025 | 27640 |
20 Jan 2025 | 27660.05 |
17 Jan 2025 | 27951.8 |
16 Jan 2025 | 27311.1 |
15 Jan 2025 | 27763.95 |
14 Jan 2025 | 28255.55 |
Company Name | ISIN Code |
---|---|
Cipla Ltd | INE059A01026 |
Torrent Pharmaceuticals Ltd | INE685A01028 |
Sun Pharmaceuticals Industries Ltd | INE044A01036 |
Divis Laboratories Ltd | INE361B01024 |
Mankind Pharma Ltd | INE634S01028 |
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Historical Revenue of Abbott India Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Net Profit of Abbott India Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Net profit of Abbott India rose 13.01% to Rs 328.01 crore in the quarter ended June 2024 as against
Read more
08 Aug 24
The key equity indices further extended gains and hit fresh record highs in mid-morning trade. The N
Read more
20 Sept 24
Vonoprazan (PCAB or potassium competitive acid blocker) addresses severe acid related disorders like
Read more
20 Sept 24
Abbott India announced the resignation of Ashok Saini as Commercial Director - GenNext, Vaccines and
Read more
18 Oct 24